Abstract
Safety of administration of a vindesine (VDS)-anti-CEA conjugate and its ability to localise after radiolabelling were investigated in patients with advanced metastatic carcinoma (4 colorectal and 4 ovarian). For imaging, patients received between 230 and 520 micrograms of 131I labelled antibody. In 5, localisation of conjugate was demonstrated, in another it was equivocal and in 2 patients, undetectable. For assessment of safety each patient also received a single dose of conjugate increasing from 1.2 to 42 mg antibody linked to 24 to 1800 micrograms VDS. The in vitro activity of the anti-CEA antibody and its ability to localise in vivo were preserved after conjugation. There was no obvious toxicity or hypersensitivity attributable to either the radiolocalisation or escalated doses of conjugate in any of the patients. The feasibility of the preparation and administration to patients of a vindesine-antibody conjugate has been demonstrated.
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Ford, C., Newman, C., Johnson, J. et al. Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer. Br J Cancer 47, 35–42 (1983). https://doi.org/10.1038/bjc.1983.4
Issue Date:
DOI: https://doi.org/10.1038/bjc.1983.4
- Springer Nature Limited
This article is cited by
-
Antibody-drug conjugates in lung cancer: dawn of a new era?
npj Precision Oncology (2023)
-
CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate
Journal of Cancer Research and Clinical Oncology (2023)
-
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Cancer Cell International (2022)
-
Recent progress in antibody–drug conjugate therapy for cancer
Nature Cancer (2022)
-
Unlocking the potential of antibody–drug conjugates for cancer therapy
Nature Reviews Clinical Oncology (2021)